4th Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics
23-24

May 2019

Vienna

Austria

Co-located with 3rd Annual Antibody Summit: Biscpecifics & Multispecifics

We are pleased to invite you to the 4th Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 23 -24, 2019 in Vienna, Austria. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on how ADCs and novel bioconjugates development can be optimised for the future. It is an honour and privilege to invite you to participate in...

We are pleased to invite you to the 4th Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 23 -24, 2019 in Vienna, Austria. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on how ADCs and novel bioconjugates development can be optimised for the future. It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Vienna in May!

more info
Who Should Attend

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders and Managers specialising in:

  • Drug Discovery
  • Manufacturing/CMC
  • Molecular Biology
  • Proteomics
  • Cell Culture
  • Antibody-drug conjugates (ADCs)
  • Immunoconjugates
  • Marine-based cytotoxins
  • Small-molecule drug conjugates
  • Nanoparticles / Nanobodies
  • PKPD
  • Toxicology
  • Assay Development
  • Translational Research
  • In Vivo
  • Oncology
  • Immunology
  • Biotherapeutics
  • Chemotherapeutics
  • Clinical Development
  • Protein Engineering
  • Medicinal Chemistry
  • Biomarkers
  • Antibody & Biologicsv
  • Bioconjugates
  • Monoclonal antibodies (mAbs)
  • Large molecule
  • Peptide-drug conjugates
  • Diabodies / Minibodies
  • ADME
  • Analytical & Formulation
  • Bioanalysis
  • In Vitro
  • Cancer
  • Haematology
  • Antibody-based therapeutics
  • Immunotherapeutics
  • Neurodegenerative Diseases
Key Practical Learning Points of the Summit

360 ° view of Antibody Drug Conjugates (ADC) from key stakeholders to leverage for the business, scientific, and tech adoption
Emerging discoveries, cutting-edge knowledge, tools, methods, technologies to design and to bring to the clinic safe, and efficient bioconjugates
Discovery, development, and bioanalytical strategies towards novel bioconjugates:
More understandable, more precise, and new targets
Alternative scaffolds and new payloads
Optimized conjugation chemistry and stability
Improved therapeutic index
Accelerating successful translation to clinic & clinical progress
Establishing robust manufacturing & supply chains

Annual

Events

Sponsors and Partners

Partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner